119th Congress · introduced in the Senate · May 12, 2025
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Official title from Congress.gov
Latest action (May 12, 2025): Read twice and referred to the Committee on Finance.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
132 citations; showing the 25 most recently posted.
NOVOCURE INC. · lobbying firm or registrant: WILLIAMS AND JENSEN, PLLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NOVOCURE INC. · lobbying firm or registrant: WILLIAMS AND JENSEN, PLLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$60,000
Paid to lobbying firm
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices. CMS RAPID Proposed Rule.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MEDTRONIC INC · lobbying firm or registrant: MEDTRONIC, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$1,610,000
Spent on own lobbying
Issues related to coverage and payment for breakthrough medical devices, including Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717; H.R. 5343) and CMS Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway proposal Issues related to coverage and payment of AI and digital…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SIEMENS MEDICAL SOLUTIONS USA, INC. · lobbying firm or registrant: AVENUE SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$70,000
Paid to lobbying firm
Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process; S. 1399, Health Tech Investmen…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EDWARDS LIFESCIENCES LLC · lobbying firm or registrant: AVENUE SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
…ssued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JOHNSON & JOHNSON SERVICES INC · lobbying firm or registrant: JOHNSON & JOHNSON SERVICES, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$2,220,000
Spent on own lobbying
…n Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Moderni…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HEARTFLOW, INC. · lobbying firm or registrant: HEARTFLOW, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$100,000
Spent on own lobbying
…ed to Medicare reimbursement; issues related to Medicare reimbursement of AI-enabled technology; Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343); Health Tech Investment Act (S. 1399/H.R. 6197); H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies App…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ADVANCED MEDICAL TECHNOLOGY ASSN · lobbying firm or registrant: ADVANCED MEDICAL TECHNOLOGY ASSN
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$1,080,000
Spent on own lobbying
Issues related to coverage of telehealth services Issues related to Medicare coverage for digital health technologies - S. 1399/H.R. 6197 Issues related to S. 1717/H.R. 5343 Ensuring Patient Access to Critical Breakthrough Products Act Issues related to S. 2761/H.R. 5269 Lab Payments and Results Act Issues related to Medi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JOHNSON & JOHNSON SERVICES, INC. · lobbying firm or registrant: ML STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
Issues related to cardiovascular health; H.R.5343 / S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025; issues related to Heart Recovery Awareness Day and H. Res. 1301, designating Februa…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · lobbying firm or registrant: EMERGENT STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$15,000
Paid to lobbying firm
Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALZHEIMER'S ASSOCIATION · lobbying firm or registrant: ALZHEIMER'S ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,400,000
Spent on own lobbying
…EFIT) Act of 2023 (S. 526/H.R. 1092 118th Congress) Essential Caregivers Act of 2025 (H.R. 6766) Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343) Linking Seniors to Needed Legal Services Act of 2025 (H.R. 6728) Amending the Rules of the House of Representatives to establish a Permanent Select…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ZIMMER BIOMET · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
…s, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ROCHE DIAGNOSTICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
…dicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MEDICAL DEVICE MANUFACTURERS ASSOCIATION · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$30,000
Paid to lobbying firm
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EDWARDS LIFESCIENCES LLC · lobbying firm or registrant: EDWARDS LIFESCIENCES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$300,000
Spent on own lobbying
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcar…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EDWARDS LIFESCIENCES LLC · lobbying firm or registrant: EDWARDS LIFESCIENCES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$300,000
Spent on own lobbying
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NOVOCURE INC. · lobbying firm or registrant: NOVOCURE INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$160,000
Spent on own lobbying
General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · lobbying firm or registrant: THE NICKLES GROUP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Issues related to Medicare coverage of breakthrough technologies. Issues related to the RAPID coverage pathway. S. 1717 / H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Issues related to Medicare durable medical equipment competitive bidding an…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHILIPS HOLDING USA INC. · lobbying firm or registrant: PHILIPS HOLDING USA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$470,000
Spent on own lobbying
…ment Act (whole bill) and H.R. 6197, the Health Tech Investment Act (whole bill) Site neutrality payments under Medicare Medicare Physician Fee Schedule reform S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act (whole bill) and H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act (whole…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL HEALTH COUNCIL · lobbying firm or registrant: NATIONAL HEALTH COUNCIL
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$21,227
Spent on own lobbying
H.R. 1, One Big Beautiful Bill Act, implementation and patient access issues. S. 1816/H.R. 3514, Improving Seniors' Timely Access to Care Act. S. 1717/H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act. H.R. 3521/S. 4440, Clinical Trial Modernization Act. S. 2903/H.R. 5509, Safe Step Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MEDICAL DEVICE MANUFACTURERS ASSOCIATION · lobbying firm or registrant: MEDICAL DEVICE MANUFACTURERS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$340,000
Spent on own lobbying
Issues related to Medicare coverage reform Issues related to the coverage for FDA Breakthrough products and the H.R. 5343 and S.1717 Ensuring Patient Access to Critical Breakthrough Products Act TCET Issues related to the Regulatory Alignment for Predictable and Immediate Device (RAPID) cove…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · lobbying firm or registrant: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Medicare/Medicaid
$90,000
Spent on own lobbying
…ment of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthr…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · lobbying firm or registrant: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Medical/Disease Research/Clinical Labs
$90,000
Spent on own lobbying
…Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE COOK GROUP INC. · lobbying firm or registrant: THE COOK GROUP INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Medicare/Medicaid
$120,000
Spent on own lobbying
Medicare Reimbursement: Medicare Coverage of Breakthrough Technologies (S. 1717/H.R. 5343); Transitional Coverage for Emerging Technologies (TCET)/Medicare Coverage for Innovative Technology (MCIT); supplies and services incident to a phys…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THERMO FISHER SCIENTIFIC INC · lobbying firm or registrant: THERMO FISHER SCIENTIFIC INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$550,000
Spent on own lobbying
…ng. H.R. 5269/S. 2761: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Managem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing